HOME >> BIOLOGY >> NEWS
JCI Table of Contents, November 3, 2003

Gene therapy establishes a TRAIL to arthritis treatment

In the November 3 issue of the Journal of Clinical Investigation, John Mountz and colleagues from the University of Alabama at Birmingham describe a gene-modified cell therapy utilizing the TRAIL molecule that successfully limits the incidence and severity of arthritis in a mouse model of collagen-induced arthritis and joint inflammation. The regime represents a therapeutic option for systemic rheumatic diseases.

Mountz and colleagues isolated dendritic cells prepared from either peripheral blood or bone marrow, which were then pulsed with collagen. The DNA of an adenovirus expressing tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) was then introduced into these cells. The design of the adenovirus vector allowed the researchers to "switch on" the expression of TRAIL by these gene-modified dendritic cells at their discretion, by the addition of doxycycline (DOX).

A cascade of immunological events including lymphocyte activation, lymphokine production, and proliferation of synovial cells (which comprise the loose connective tissue lining the joint cavity) is associated with collagen-induced arthritis in mice. Mountz and colleagues found that infusion of collagen-pulsed DOX-inducible TRAIL-expressing dendritic cells into these mice induced the apoptosis of collagen-specific T cells, a reduction in lymphokine production, and suppression of collagen-induced arthritis. The data suggest that this gene therapy regime is a safe and effective method for inhibiting the development of collagen-induced arthritis

In an accompanying commentary in the same issue, George and Maria Tsokos from the Walter Reed Army Institute of Research, Maryland, discuss how the results of Mountz and colleagues propose new possibilities for gene-modified cellbased treatment of rheumatoid arthritis.

TITLE: CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
3-Nov-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, 1 October, 2003
4. JCI Table of Contents, September 15, 2003
5. JCI Table of Contents
6. JCI Table of Contents, 15 August 2003
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... May 23, 2017 , ... ... technology applications, has announced a facility expansion to accommodate its rapid growth. , ... of new workspace and renovation of the existing areas. The expansion includes, a ...
(Date:5/23/2017)... ... , ... Bacterial biofilms, surface adherent communities of bacteria that are encased in ... poisoning and catheter infections to gum disease and the rejection of medical implants. ... per year, there is currently a paucity of means for preventing their formation or ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... re-engineer their control technology again and again. METTLER TOLEDO has released two new ... The videos illustrate how integration of the ACT350 into Siemens and Allen Bradley ...
(Date:5/22/2017)... ... May 22, 2017 , ... Baltimore biotech firm, PathSensors, ... Biohealth community in developing and issuing recommendations to grow Maryland's biohealth industry and ... by 2023. , The recommendations are contained in a report ...
Breaking Biology Technology:
Cached News: